Daewoong Pharmaceutical Repeatedly Discovers Botulinum Strain... Success in Soil Beneficial Microorganism Exploration Project

Daewoong Pharmaceutical and Noah Biotech Successfully Isolate Botulinum Toxin Type A Strain from Domestic Livestock Farms
Discovery Confirms Commercial Potential and Genetic Identity with Global Strains
Plans to Distribute Strains to Research Institutions to Boost Korea's Botulinum Industry

Daewoong Pharmaceutical Headquarters. Photo by Daewoong Pharmaceutical

Daewoong Pharmaceutical announced on the 24th that through a soil beneficial microorganism discovery project conducted with Noah Biotech, they discovered and isolated a Botulinum toxin type A strain and confirmed its potential for commercial toxin production.

The research team at Noah Biotech collected samples primarily from domestic livestock farms suspected of botulism outbreaks due to severe contamination or animal deaths. Among these samples, they successfully isolated and identified a Botulinum toxin type A strain and have completed reporting to the Korea Disease Control and Prevention Agency and the Ministry of Trade, Industry and Energy.

Noah Biotech is a bio company established with the goal of exploring, isolating, and securing beneficial microorganisms to help improve quality of life. This isolation and identification was promoted as part of a project to secure beneficial soil microorganisms in collaboration with Daewoong Pharmaceutical.

Daewoong Pharmaceutical confirmed through genetic analysis of the strain secured by Noah Biotech that the sequence of the toxin gene region is completely identical to those of existing strains from the United States and Europe. They also confirmed that the strain produces toxins at a level sufficiently suitable for commercial use. This once again proves that commercially viable Botulinum toxin type A strains are widely distributed in domestic nature and can be isolated and identified without difficulty.

With this, Daewoong Pharmaceutical has secured seven types of Botulinum strains domestically and internationally. They plan to continue active research on strains and processes as a specialized Botulinum company. Additionally, to contribute to the advancement of basic Botulinum research in Korea and to promote collaboration between companies, they are considering freely distributing the strains to research institutions wishing to utilize them, subject to approval from relevant authorities. Through this, they hope to further activate the domestic Botulinum toxin industry and strengthen global competitiveness.

Daewoong Pharmaceutical plans to build a diverse toxin lineup based on strains discovered domestically and those imported from abroad, aiming to establish itself as a leading company in the Botulinum toxin industry.

A Daewoong Pharmaceutical official emphasized, "We will continuously strengthen the competitiveness of K-toxin in the global market through relentless research and development."

This content was produced with the assistance of AI translation services.